Last updated: 02/04/2020 18:50:08

PAZOPANIB FOR THE FIRST AND SECOND LINE TREATMENT OF ADVANCED STAGE PATIENTS WITH GOOD TO INTERMEDIATE RISK RENAL CELL CARCINOMIA: A COST MINIMIZATION ANALYSIS

GSK study ID
117348
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: PAZOPANIB FOR THE FIRST AND SECOND LINE TREATMENT OF ADVANCED STAGE PATIENTS WITH GOOD TO INTERMEDIATE RISK RENAL CELL CARCINOMIA: A COST MINIMIZATION ANALYSIS
Trial description: The indirect statistical comparisons between pazopanib and the comparators will be performed using two unique approaches. The first indirecrt comparsion will be a meta-regression analysis on all the relevant clinical outcomes and the number of withdrawals caused by adverse drug reactions reported in the trials.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Progression Free Survival

Timeframe: 24 weeks

Secondary outcomes:

Overall Survival

Timeframe: 5 years

Interventions:
Drug: pazopanib
Drug: Sorafenib
Drug: interferon
Drug: everolimus
Drug: Sunitinib
Drug: temsirolimus
Enrollment:
0
Observational study model:
Other
Primary completion date:
2013-26-08
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Carcinoma, Renal Cell
Product
pazopanib
Collaborators
Augmentium Pharma Consulting
Study date(s)
November 2010 to August 2013
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
none
  • Clinical trials with at least 50 patients enrolled into each arm which consisted of either active therapy or placebo.
  • Adult patients
Inclusion and exclusion criteria
Inclusion criteria:
  • Clinical trials with at least 50 patients enrolled into each arm which consisted of either active therapy or placebo.
  • Adult patients
  • Patients must have been treatment naive or had received only one prior cytoline-based therapy.
  • The promary and secondary endpoint must have been progression free survival and overal survival.

Trial location(s)

No location data available.

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Finalized
Actual primary completion date
2013-26-08
Actual study completion date
2013-26-08

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website